August 28th 2025
The authors examine common FDA 483 findings and outline strategies to address and prevent regulatory non-compliance.
Bristol-Myers Squibb Issues Voluntary Recall of Carmustine for Overfilled Vials
September 4th 2012Bristol-Myers Squibb has initiated a voluntary recall of 10 lots of BiCNU (carmustine for injection) previously manufactured by Ben Venue Laboratories, a former, third-party contract manufacturer for the company, to the user level.
Early Development GMPs for Stability (Part IV)
IQ Consortium representatives explore and define common industry approaches and practices for applying GMPs in early development, with a focus on stability.
Plant Focus: High-Potency Manufacturing and Sustainability at Pfizer
September 1st 2012Pfizer has two manufacturing facilities in Germany for high-potency manufacturing, respectively in Freiburg and Illertissen. Pharmaceutical Technology's Executive Editor Patricia Van Arnum visited the facilities and spoke to the company about the design and operation of these facilities.
Winds of Change at the International Society of Automation Summit
August 29th 2012The International Society of Automation’s (ISA’s) 7th Marketing and Sales Summit, held Aug. 15–17, 2012 in Austin, Texas, was themed “New Rules of Customer Engagement: Riding the Winds of Change”, and emphasized the need to adapt to the changing needs, expectations, and behaviors of marketplace decision makers, according to an Aug. 27, 2012 press release.
Pfizer and Mylan Partner to Develop Generic Drugs in Japan
August 27th 2012Pfizer and Mylan have agreed to establish an exclusive long-term collaboration to develop, manufacture, distribute, and market generic drugs in Japan. The products included in the collaboration are expected to be sold under the Pfizer brand with joint labeling.